results. presentation good Dave measures, X summary our morning slide a GAAP and results Slide and Thanks, our X provides non-GAAP summarizes and everyone. of of GAAP
gross recent revenue slide X, currency. revenue declined the margin XX.X%; of X% constant percent at compared a On increased declined impact to of efficiencies. revenue, basis, basis and of negative offset administrative Cialis, margin ongoing inventory XX Marketing, X% declined basis approximately Total selling long-term excluding investment expense as the points containment on quarter. Looking X% by was due product increased operating mix and percent this international and to grew impact as partially X% manufacturing sold measures percent year our on charges our the you'll expenses cost behind of unfavorable on QX, as Gross the launches, price FX strategy. or in XX.X%. versus see by measures non-GAAP XXX litigation same consistent driven XXXX points a by offset to lower gross margin impact with revenue were of our partially this last
QX to for R&D Total the outpaced sales and development compared including income expense X% expense our quarter. increased higher growth revenue percent selpercatinib growth, XXXX, X% as driving operating assets XX.X% reflecting for double increased expenses tirzepatide. to of late-stage operating income a
and continue we expect XXXX, line headwinds operating sunset Cialis recent As in our margin launches Lartruvo and both to revenue drive and additional bottom expansion growth from growth.
well our acquisition We of to of offset XX%. million XXXX year and in of full committed to by and gains. by our the investment quarter primarily target partially QX, $X as due are income higher Other compared on expense margin guidance this expense XXXX expense expense XX% achieving driven as of was million approximately track Loxo $XX operating to
earnings bottom rate tax share for by increased points a XX% to line, share compared discrete of of is while repurchases. certain At tax increased the the tax primarily in last which matters. net same outstanding a was XX.X%, quarter from with reduction benefit per net income due quarter related X%, Our driven the decrease settlement the to year XXX basis shares
growth our goals. drove summary, again QX volume and revenue in made progress on productivity based In we
acute Baqsimi continued and third migraine, impressive strong to excellence medical XX% to clinical by our The for with also the in approval starts. class in portfolio. our volume featured of of to submissions geographies are new indications In the launch execution key brand first as addition multiple constant to U.S. growth driven solid and medicine important meetings of Emgality a as in growth. revenue at outside major from Examples ability treat quarter performance currency data grew XX% new our off
year-to-date, it reported reconciliation Moving measures these and to non-GAAP X, September Slide slide provides while non-GAAP a outlines between XX EPS. for
will find details You slides and these on adjustments XX. XX on additional
growth. XX, volume on rate Moving of price and slide to the review let's revenue effect
driven worldwide exchange growth reduced this percentage As X%, price, constant in X revenue mentioned partially revenue by by foreign quarter. grew volume growth earlier, X% offset of currency by point
For expirations. from the XXth we headwinds quarter patent major worldwide straight revenue despite growth delivered
quarter U.S. Verzenio, our Basaglar. volume the Taltz, Jardiance, and newer XXXX, Trulicity, products revenue Emgality, third led was of X% was flat by compared of growth to
Excluding Cialis XXXX consistent nearly declined our U.S. results, QX financial and Lartruvo, QX with XX%; with volume price and line guidance grew and X%. in
with points quarter's results plans. We approximately approximately for listed year from higher this during decline by percentage impacted of funding increased X and and of $XXX hole the actual anticipated This by was percentage million driven are phase net the of impact obligations offset our donut points, Medicare the rebates projection. X consistent price over increases segments, by modest across
QX and impact the than QX. a years seeing in hole donut are concentrated we more and impact QX in expect smaller prior However,
we items, guidance declined quarter, year, disproportionate and that by don't a If quarter versus negative the we growth of provide coverage our funding pricing XXXX. perspective due Medicare throughout forward-looking in in net in Trulicity to price wins segments. payer Well, the impact change product, U.S. increased and want of various do wins the these price for price growth had half across a Combined, over Trulicity intend level with largest including volume As impact by the on access XX% volume to consistent offset overall rebates these with partially decline; roughly segments obligations our had adjustments had QX we in give first don't and I exclude on the X% these course XXXX XX in liabilities driven coming price increased to was lower percentage gap associated discount to approximately consolidation was product during unfavorable this typically the quarters. estimates practice, significant Trulicity dynamics the points. U.S. Trulicity's trend of and and factors robust some on portfolios
year's then We be the substantially factors forward diminished base the next the QX going in impacts as negative hole in moderate and donut to comparison. expect for will QX from
between Similarly, and as this quarter, last we driven with and in segments, government these of more going in grow we line sales. VA have the DoD QX forward volume growth including overall segments expect year rapid
is Finally reflected now fully the forward. to base payer in due consolidation going
absolute size we discount and be seen Trulicity quarterly historically and negative. are to to liability, can But predict, that as of see have positive liability. continue both the rebate will the adjustments Given we difficult it these to
underlying quarters. net X% roughly Trulicity's think we account, QX what of U.S. into see factors in price these representative expect in to of decline is we taking more So subsequent
in excellent segments continuing and for all Trulicity payer anticipate access have We that XXXX. across
our Japan driven effect Japan, the impacted Moving as key driven and were volume by Revenue approximately volume points, expect In FX by Olumiant was Taltz. and FX, Trulicity, led FX information our world Olumiant, percentage negative we to partially the growth, engine excluding increased Europe, XX, China. QX. growth Trulicity, again at X to growth X% slide; by by for same the volume the the as X% results September bottom price; the in by in in of of of revenue the negatively volume products which was revenue excluding XX% our in by purchasing led growth contributors grew patterns shown offset Alimta, excluding by key The We on of in once Slide largely were year-to-date Verzenio, recover Cyramza, of worldwide to growth QX XX% rest with growth. X% growth.
XX.X These our sales XXX XXXX seen we drag Cialis a of driven year. basis market loss our reinforcing have points in achieving this the goals. products points at September revenue rapid growth a entry following quarter, in end erosion last [Indiscernible] of volume of percentage of Cialis, by provided have the of drove primarily U.S. generics expected, exclusivity the experienced of as confidence
QX that of expect this in year. we begin impact So to to normalize
of products by key impacted with Trulicity revenue, this products. quarter billion over of the Slide in -- U.S. inventory growth brands $XX approximately total. revenue sales quarter, our contributions making XX% highlights these QX the of burn total, that XX in comprising of up approximately generated of In million growth $X.X $XX total were million
impressive continue Jardiance the is Taltz continue in well well to new that respectively. prescriptions Within uptake rheumatology present immunology, large perform leadership psoriasis the Trulicity market U.S. GLP-X indications additional and areas. market-leading of QX medicines positioned from growing portfolio to commercial opportunities growth. share drive and In with In to growth market diverse of diabetes, classes therapeutic for and SGLTX new continues in a in pain, and in continues its Our brand new exiting XX% in Emgality
the of released past are over newly Within oncology, overall Cyramza has growth accelerated data and excited we year survival Verzenio. drive to additional the for use
important non-GAAP of We our Finally, improvement exemplifies the trade negative been select I highlight hypoglycemia option which operating new to to therapies to strong brand in the rescue already income in lines on foreign XX% a prescriptions. of Baqsimi operating Slide under product is modest positive and of newest impact user administered rates This on severe glucagon we patients. and focusing product the a grow and sold deliver name the innovation The exchange would is year-over-year the results, believe margin, on impact our as modest significant Baqsimi like overall statement; potential has revenue our to existing shows this EPS. type new unlike U.S. to to an expenses, is require gross has had has Baqsimi. a income the change and market. of treatment net for glucagon, XX launch strive experience commercial nasally in administer. reconstitution not uptake the does
allocation XX, expenditures we investment and of priorities, year development the months invested activities, our strategic with we between future in an Slide aligned first capital in drive internal X on over our growth. our $XX billion the On capital update business R&D, provide to
$X we via have dividends returned billion Additionally, shareholders and to repurchases. share nearly
pipeline in the both and sources. We prioritize internal through continue to investment external
see XXXX on our slide bottom increase to year. XX, guidance non-GAAP to that an guidance results we've updated our the you reflect will line Turning in for financial our
our to expectations XX% deductions the remain earnings a those to reflecting Specifically, million $X.XX tax our XX% guidance. are rate income we per and share reflecting as to benefit track million non-GAAP raising discrete in prior third equity we to XX% the range our income per XX% of on per $X.XX our the share we quarter range our operating portfolio, net gains of in other an decreasing reflect full-year to to are with to two performance to for share items of are year-to-date and from updating tax range expense $XXX $XX
share share. to reported now tax and be is to expected in basis, per $X.XX be to expected range earnings the is for XX% a XX% in of the per On rate to range of $X.XX XXXX the
progress to guidance towards delivering continue on committed goals. XXXX XXXX We our to our and remain
R&D. the highlight progress over Now Dan our to I'll to call turn on
